



Glucose Intolerance on Pheochromocytoma and Paraganglioma – The Current Understanding and Clinical Perspectives

Ichiro Abe^{1,2}, Farhadul Islam³ and Alfred King-Yin Lam^{1*}

¹ Cancer Molecular Pathology of School of Medicine, Griffith University, Gold Coast, QLD, Australia, ² Department of Endocrinology and Diabetes Mellitus, Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan, ³ Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh

OPEN ACCESS

Edited by:

Olfa Masmoudi-Kouki,
University Tunis El Manar, Tunisia

Reviewed by:

Hiroshi Ikegami,
Kindai University, Japan
Masaru Doi,
Doi Internal Medicine Clinic, Japan

*Correspondence:

Alfred King-Yin Lam
a.lam@griffith.edu.au

Specialty section:

This article was submitted to
Neuroendocrine Science,
a section of the journal
Frontiers in Endocrinology

Received: 11 August 2020

Accepted: 30 October 2020

Published: 26 November 2020

Citation:

Abe I, Islam F and Lam AK
(2020) Glucose Intolerance
on Pheochromocytoma
and Paraganglioma – The
Current Understanding and
Clinical Perspectives.
Front. Endocrinol. 11:593780.
doi: 10.3389/fendo.2020.593780

Half of the patients with pheochromocytoma have glucose intolerance which could be life-threatening as well as causing postoperative hypoglycemia. Glucose intolerance is due to impaired insulin secretion and/or increased insulin resistance. Impaired insulin secretion is caused by stimulating adrenergic α_2 receptors of pancreatic β -cells and increased insulin resistance is caused by stimulating adrenergic α_1 and β_3 receptors in adipocytes, α_1 and β_2 receptors of pancreatic α -cells and skeletal muscle. Furthermore, different affinities to respective adrenergic receptors exist between epinephrine and norepinephrine. Clinical studies revealed patients with pheochromocytoma had impaired insulin secretion as well as increased insulin resistance. Furthermore, excess of epinephrine could affect glucose intolerance mainly by impaired insulin secretion and excess of norepinephrine could affect glucose intolerance mainly by increased insulin resistance. Glucose intolerance on paraganglioma could be caused by increased insulin resistance mainly considering paraganglioma produces more norepinephrine than epinephrine. To conclude, the difference of actions between excess of epinephrine and norepinephrine could lead to improve understanding and management of glucose intolerance on pheochromocytoma.

Keywords: pheochromocytoma, glucose intolerance, insulin secretion, insulin resistance, paraganglioma

INTRODUCTION

Pheochromocytoma is a neuroendocrine tumor derived from chromaffin cells in the adrenal medulla that produces catecholamines (1, 2). There are recent advances on molecular pathogenesis as well as on the clinical perspectives in the tumor (1, 3). Common clinical complications in patients with pheochromocytoma include hypertension, glucose intolerance, and cardiovascular dysfunctions (4). Among these complications, glucose intolerance attracts attention as recent developments noted regarding the mechanisms. Commonly, glucose intolerance is known for its hyperglycemia due to impaired glucose homeostasis, which is a result of impaired insulin secretion and/or increased insulin resistance (5, 6). In patients with pheochromocytoma, Wilber and co-workers reported that insulin secretion was inhibited by

an excess of catecholamine (7). In addition, Deibert and co-workers showed that insulin resistance was increased by excess catecholamine (8). Thus, impaired insulin secretion as well as increased insulin resistance could affect glucose intolerance in patients with pheochromocytoma. Recent studies started to elucidate the mechanisms of glucose intolerance in pheochromocytoma. In this review, we aim to summarize these recent findings of glucose intolerance in patients with pheochromocytoma.

GLUCOSE INTOLERANCE ON PHAEOCHROMOCYTOMA: INCIDENTS AND ISSUES

Glucose intolerance is one of the complications of pheochromocytoma and often found in patients with pheochromocytoma (9, 10). Elenkova and co-workers revealed that half of the patients (93/186) with pheochromocytoma had glucose intolerance (11). Beninato and co-workers also investigated 153 patients with pheochromocytoma, showing that 23% (n=36) had diabetes mellitus. Of these, and 79% (n=33) had complete resolution of diabetes mellitus after extirpation of pheochromocytoma (12).

Elenkova and co-workers indicated that patients with glucose intolerance had increased urine metanephrine (metadrenaline; metabolite of epinephrine/adrenaline) and normetanephrine (a metabolite of norepinephrine/noradrenaline) and were older than those without glucose intolerance (11). There were no significant differences among the two groups with respect to tumor size and body mass index. On the other hand, Beninato and co-workers indicated patients with diabetes mellitus had larger tumors than those without diabetes mellitus but there was no significant difference between the two groups in patients' age and catecholamine values (12). Considering the different results of two studies, it remains controversial about the relationship between the incidence of glucose intolerance and the other clinical parameters. Thus, it is difficult to predict the risk of glucose intolerance in patients with pheochromocytoma.

Almost all of the patients treated as diabetes mellitus before diagnosed pheochromocytoma were initially diagnosed as type 2 diabetes mellitus. Glucose intolerance in patients with pheochromocytoma is often difficult to be well-controlled and insulin therapy is sometimes needed. Nevertheless, a few cases were diagnosed as type 1 diabetes mellitus because of their impaired insulin secretion and necessity of insulin therapy (13, 14). In addition, the clinical manifestations of glucose intolerance in patients with pheochromocytoma are sometimes severe. There were some cases of diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome, which could be lethal without accurate therapy in patients with pheochromocytoma (15–17). These previous reports indicated glucose intolerance in patients with pheochromocytoma could exhibit severe phenotypes and must not be overlooked.

Glucose intolerance of pheochromocytoma is a problem in the perioperative period. After tumor extirpation, hypoglycemia occurs to some patients with pheochromocytoma. Akiba and

co-workers demonstrated that 13% of patients had severe hypoglycemia after extirpation of pheochromocytoma. This postoperative hypoglycemia is likely due to a sharp decrease of catecholamines by tumor extirpation (18). Recently, Araki and co-workers showed patients who had higher epinephrine and those who had glucose intolerance preoperatively were more likely to develop postoperative hypoglycemia, which indicated patients with higher epinephrine and glucose intolerance must be careful observation in the perioperative period (19).

THE MOLECULAR ADRENERGIC MECHANISMS RELATED TO GLUCOSE INTOLERANCE AND THE DIFFERENCES AMONG TYPES OF CATECHOLAMINE EXCESS IN GLUCOSE INTOLERANCE

Multifarious adrenergic receptor ($\alpha 1$, $\alpha 2$, $\beta 1$, $\beta 2$, and $\beta 3$) and their different functions were noted in various organs (20). In patients with pheochromocytoma, various adrenergic receptors were reported to be responsible for the glucose intolerance (21–26). Impaired secretion of insulin by catecholamines on pheochromocytoma is caused mainly through adrenergic $\alpha 2$ receptors of β -cells in pancreatic islets (21, 22). The $\alpha 2$ receptors are divided into 3 subtypes ($\alpha 2A$, $\alpha 2B$, and $\alpha 2C$). Among them, $\alpha 2A$ receptors were reported to suppress insulin secretion from pancreatic β -cells. Fagerholm and co-workers showed that adrenergic $\alpha 2A$ receptor knockout mice or adrenergic $\alpha 2$ receptor antagonists exhibit elevated insulin levels and reduced glucose levels (21).

On the other hand, increased insulin resistance on pheochromocytoma is caused by stimulated gluconeogenesis and glycogenolysis in the liver, which arises from an excess of glucagon and increase of free fatty acids as well as elevated glucose uptake in skeletal muscle. Stimulation of adrenergic $\beta 2$ and $\alpha 1$ receptors of the pancreatic α -cells causes an increase in glucagon secretion (21, 23–25). Two previous *in vitro* studies demonstrated stimulation of adrenergic β receptors could increase glucagon secretion through elevated intracellular cAMP and Ca^{2+} signaling (23, 24). Among the β receptors, Philipson showed adrenergic $\beta 2$ receptors could have most effects on glucagon secretion among adrenergic β receptors (25). Vieira and co-workers showed adrenergic $\alpha 1$ receptors antagonists stimulated glucagon secretion (23). In addition, they also showed adrenergic $\alpha 2$ receptor antagonists and agonists did not affect glucagon secretion although it was reported adrenergic $\alpha 2$ receptors were detected in pancreatic α -cells (21, 23).

In adipocytes, stimulation of the adrenergic $\beta 3$ and $\alpha 1$ receptors affects the production of fatty acids (26, 27). de Souza and co-workers showed stimulation of adrenergic $\beta 3$ receptors increased intracellular cAMP and elevated lipolysis, which caused increased fatty acid (26). In addition, Boschmann and co-workers showed that stimulation of adrenergic $\alpha 1$ receptors with adrenergic $\alpha 1$ receptor agonists led to promoting lipolysis and results in increased fatty acid (27).

Regarding glucose uptake in skeletal muscle, Shi and co-workers showed stimulating adrenergic $\alpha 1$ receptors increased glucose uptake in skeletal muscle with elevated leptin signaling with adrenergic $\alpha 1$ receptors deficient and transgenic mice (28). Shiuchi and co-workers also showed that adrenergic $\beta 2$ receptors in skeletal muscle could mediate induction of glucose uptake in skeletal muscle by leptin signaling investigating adrenergic β receptor-deficient mice and forced expression of adrenergic $\beta 2$ receptors (29). In addition, Mukaida and co-workers showed stimulating adrenergic $\beta 2$ receptors which promoted glucose transporter type 4 (GLUT4) translocation (a protein acts as glucose transporter found in adipose tissue and striated muscles) and glucose uptake in skeletal muscle using adrenergic $\beta 3$ receptor-deficient mice with adrenergic $\beta 2/\beta 3$ receptor agonists (30).

Epinephrine and norepinephrine were reported to have different affinities to respective adrenergic receptors. Epinephrine was reported to have a higher affinity to adrenergic $\alpha 2$ and $\beta 2$ receptors than norepinephrine. On the contrary, norepinephrine was reported to have a higher affinity to adrenergic $\alpha 1$ and $\beta 1$ receptors than epinephrine. Moreover, epinephrine and norepinephrine were reported to have a similar affinity to adrenergic $\beta 3$ receptors (31).

These molecular findings indicated an excess of catecholamine in pheochromocytoma could lead to both impaired insulin secretion and increased insulin resistance through various adrenergic receptors as well as different actions between epinephrine and norepinephrine in them (Table 1, Figure 1).

CLINICAL STUDIES: IMPAIRED INSULIN SECRETION AND INCREASED INSULIN RESISTANCE IN PATIENTS WITH PHAEOCHROMOCYTOMA

Clinical studies revealed patients with pheochromocytoma had impaired insulin secretion (32–34). Komada and co-workers demonstrated impairment of insulin secretion, particularly in an early phase of the insulin secretory response in 13 patients with pheochromocytoma/paraganglioma (extra-adrenal pheochromocytoma) (11 with pheochromocytoma and two with paraganglioma) (32). They noted that improved insulin secretion after surgical removal of pheochromocytoma/paraganglioma with hyperglycemic clamps as well as an oral glucose tolerance test. Moreover, the study investigated insulin resistance with hyperinsulinemic-euglycemic clamps and

homeostasis model assessment of insulin resistance (HOMA-IR), which is surrogated marker of insulin resistance. There were no significant changes of insulin sensitivity index on hyperinsulinemic-euglycemic clamps from pre-operation to post-operation although postoperative HOMA-IR value was significantly improved than preoperative value, which indicated increased insulin resistance in patients with pheochromocytoma was controversial in the study (32).

Petrák and co-workers demonstrated impaired insulin secretion and glucose intolerance in patients with pheochromocytoma using meal test and the homeostasis model assessment of β -cell function (HOMA- β), which is surrogated marker of insulin secretion. In the study, they indicated that impaired insulin secretion could be due to impaired glucagon-like peptide 1 (GLP-1) secretion (33) (Figure 1). Meanwhile, the study revealed significant increment of glucagon value and no changes in insulin/glucagon ratio between the preoperative and postoperative period. Commonly, GLP-1 decreases glucagon secretion (34). Considering excess of catecholamine leads to elevation of glucagon through adrenergic $\beta 2$ and $\alpha 1$ receptors together, the results of the study about glucagon secretion might indicate there exists some unknown mechanism of glucagon secretion in patients with pheochromocytoma (Figure 1).

There were clinical studies which revealed insulin resistance improved after adrenalectomy in patients with pheochromocytoma as well as those related to the improvement of insulin secretion (35–38). Blüher and co-workers demonstrated increased insulin resistance in three patients with pheochromocytoma having hyperglycemia medicated with anti-diabetic agents, which improved after surgical removal of pheochromocytoma (35). A follow-up study by the same group revealed an excess of catecholamine-induced glucose intolerance through increased insulin resistance with the hyperinsulinemic-euglycemic clamp study in 10 patients with pheochromocytoma (36). Moreover, Diamanti-Kandarakis and co-workers investigated glucose intolerance in 5 patients with pheochromocytoma using oral glucose tolerance test and hyperinsulinemic-euglycemic clamp. The results demonstrated not only the improvement of glucose intolerance but also reduced insulin resistance by tumor extirpation (37). Recently, Guclu and co-workers investigated 44 patients with pheochromocytoma using HOMA-IR and noted 65.9% of them (29 patients) had increased insulin resistance (38). Considering the results of these studies, both impaired insulin secretion and increased insulin resistance could induce glucose intolerance in patients with pheochromocytoma. However, it has

TABLE 1 | Different effects on glucose intolerance among adrenergic receptors.

Adrenergic receptors	Mechanism of effect on glucose intolerance	Affinity of epinephrine and norepinephrine
$\alpha 1$ receptors	fatty free acid \uparrow , glucagon secretion \uparrow , glucose uptake in skeletal muscle \uparrow , GLP-1 secretion \downarrow	Norepinephrine > Epinephrine
$\alpha 2$ receptors	insulin secretion \downarrow , GLP-1 secretion \downarrow	Epinephrine > Norepinephrine
$\beta 1$ receptors	GLP-1 secretion \uparrow	Norepinephrine > Epinephrine
$\beta 2$ receptors	glucagon secretion \uparrow , glucose uptake in skeletal muscle \uparrow	Epinephrine > Norepinephrine
$\beta 3$ receptors	fatty free acid \uparrow	Epinephrine = Norepinephrine

GLP-1, glucagon-like peptide-1.




FIGURE 1 | Summary of glucose intolerance on pheochromocytoma. GLP-1, glucagon-like peptide-1. *The clinical study demonstrated GLP-1 secretion could be suppressed on pheochromocytoma. Meanwhile, *in vivo* and *in vitro* studies showed epinephrine could increase GLP-1 secretion through adrenergic α_1 , α_2 , and β_1 receptors and norepinephrine could inhibit GLP-1 secretion through adrenergic α_1 and/or α_2 receptors. #GLP-1 inhibits glucagon secretion in pancreatic α -cells commonly, while glucagon secretion was suppressed in the clinical study which investigated GLP-1 secretion on pheochromocytoma. Considering both epinephrine and norepinephrine could increase glucagon secretion in pancreatic α -cells directly together, the study did not clarify whether increased GLP-1 secretion on pheochromocytoma could inhibit glucagon secretion in pancreatic α -cells or not.

remained unclear whether the main factor of glucose intolerance is impaired insulin secretion or increased insulin resistance.

Glucose intolerance in patients with pheochromocytoma could be improved by tumor extirpation. Meanwhile, there could be cases who could not receive tumor removal because of their complications or having metastatic phenotypes. Diamanti-Kandarakis and co-workers showed administrations of non-selective adrenergic α blocker and β blockers could improve glucose intolerance in patients with pheochromocytoma, while the effects of the agents were significantly lower than those of tumor extirpation (37). This study indicated glucose intolerance in patients who could not undergo tumor removal could be difficult only by agents of adrenergic receptor antagonists.

THE NEW INSIGHT: DIFFERENCES IN THE ACTIONS ON GLUCOSE INTOLERANCE AMONG TYPES OF THE EXCESS OF CATECHOLAMINE ON PHAEOCHROMOCYTOMA

DiSalvo and co-workers showed epinephrine could have more effects on hyperglycemia than norepinephrine based on the

investigation of infusion epinephrine and norepinephrine into healthy humans (39). However, there was no clinical study on the differences in the mechanisms between excess of epinephrine and that of norepinephrine on glucose intolerance in patients with pheochromocytoma.

A recent study elucidated the differences in the actions between epinephrine and norepinephrine on glucose intolerance in patients with pheochromocytoma (40). The study investigated the association between the changes of urinary metanephrine/normetanephrine (metabolic product of epinephrine/norepinephrine) and those of HOMA- β /HOMA-IR from pre-operation to post-operation in 12 patients with pheochromocytoma. The study revealed that pheochromocytoma could lead to glucose intolerance by both impaired insulin secretion and increased insulin resistance. Furthermore, the study demonstrated there could be the differences in the actions on glucose intolerance between excess of epinephrine and that of norepinephrine. The results indicated an excess of epinephrine could affect glucose intolerance mainly by impaired secretion of insulin and that of norepinephrine could affect glucose intolerance mainly by increased insulin resistance. Regarding impaired insulin secretion, the results could be explained by the molecular mechanisms which epinephrine has a higher affinity to adrenergic α_2 receptors than norepinephrine. Considering increased insulin

resistance, norepinephrine could have stronger effects than epinephrine on increased fatty acids due to lipolysis in adipocytes, which were through adrenergic β_3 and α_1 receptors. Seeing the contrary affinities to adrenergic α_1 and β_2 receptors between epinephrine and norepinephrine on glucagon secretion as well as glucose uptake in skeletal muscle together, the results of the clinical study about increased insulin resistance could be consistent with the molecular mechanisms (Figure 1).

Hence, the study of different types of the excess of catecholamine should be important for understanding the mechanism of glucose intolerance in patients with pheochromocytoma. It is also possible that types of the excess of catecholamine affects GLP-1 secretion on pheochromocytoma. Regarding the association between GLP-1 secretion and excess of catecholamine, there were two previous *in vivo* and *in vitro* studies (41, 42). The *in vitro* study indicated epinephrine could increase GLP-1 secretion through adrenergic α_1 , α_2 , and β_1 receptors, whereas the *in vivo* study indicated norepinephrine could inhibit GLP-1 secretion through adrenergic α_1 and/or α_2 receptors (41, 42) (Table 1, Figure 1). These studies indicated differences in effects on GLP-1 secretion between epinephrine and norepinephrine could exist. Petrák and co-workers did not investigate the different effects on GLP-1 secretion between excess of epinephrine and that of norepinephrine (33). Hence, future studies about the association between GLP-1 and the type of excess of catecholamine might reveal further knowledge of GLP-1 secretion on pheochromocytoma. Furthermore, they might lead to clarification of the mechanism of increased glucagon secretion after extirpation of pheochromocytoma, which was seen in the study by Petrák and co-workers.

GLUCOSE INTOLERANCE ON PARAGANGLIOMA

Paragangliomas is extra-adrenal non-epithelial tumors originating from neural crest-derived paraganglion cells located in the region of autonomic nervous system ganglia and accompanying nerves with histology like pheochromocytoma (3). Regarding glucose intolerance in paraganglioma, Elenkova and co-workers noted that 44% (8/18) of patients with paraganglioma had glucose intolerance (11). However, there were no other studies investigating glucose intolerance focused on paraganglioma

including differences between glucose intolerance on pheochromocytoma and that on paraganglioma. The mechanism of glucose intolerance on paraganglioma had never been investigated in clinical studies in the English literature. di Paolo and co-workers previously reported the case of extra-adrenal pheochromocytoma (paraganglioma) with glucose intolerance due to increased insulin resistance (43). The case had also high norepinephrine secretion. Commonly, paraganglioma produces more norepinephrine than epinephrine (44). Considering the different actions on glucose intolerance between epinephrine and norepinephrine, glucose intolerance in patients with paraganglioma could be caused by increased insulin resistance mainly as the reported case.

CONCLUSION

In this article, current perspectives about glucose intolerance in patients with pheochromocytoma were presented along underlying the mechanism of glucose intolerance. The findings indicated that patients with pheochromocytoma could have both impaired insulin secretion and increased insulin resistance by an excess of catecholamine. However, the definite mechanism remains unknown, and it has been controversial whether the main factor of glucose intolerance is impaired insulin secretion or increased insulin resistance. Recent advances from the viewpoint of the difference of actions between excess of epinephrine and that of norepinephrine could clarify this controversy. A larger cohort of patients is required to investigate the mechanism and effects of hyperglycemia in pheochromocytoma and paraganglioma.

AUTHOR CONTRIBUTIONS

IA wrote the first draft of the manuscript. FI and AKL revised and edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

Funding from private practice funding account in Griffith University.

REFERENCES

- Lam AK. Updated on paragangliomas and pheochromocytomas. *Turk Patoloji Derg* (2015) 31:105–12. doi: 10.5146/tjpath.2015.01318
- Walther MM, Keiser HR, Linehan WM. Pheochromocytoma: evaluation, diagnosis, and treatment. *World J Urol* (1999) 17:35–9. doi: 10.1007/s003450050102
- Lam AK. Update on Adrenal Tumors in 2017 World Health Organization (WHO) of Endocrine Tumors. *Endocr Pathol* (2017) 28:213–27. doi: 10.1007/s12022-017-9484-5
- Reisch N, Peczkowska M, Januszewicz A, Neumann HP. Pheochromocytoma: presentation, diagnosis and treatment. *J Hypertens* (2006) 24:2331–9. doi: 10.1097/01.hjh.0000251887.01885.54
- Virally M, Blicklé JF, Girard J, Halimi S, Simon D, Guillausseau PJ. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. *Diabetes Metab* (2007) 33:231–44. doi: 10.1016/j.diabet.2007.07.001
- Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. *Endocr Rev* (1998) 19:477–90. doi: 10.1210/edrv.19.4.0336
- Wilber JF, Turtle JR, Crane NA. Inhibition of insulin secretion by a pheochromocytoma. *Lancet* (1966) 2:733. doi: 10.1016/s0140-6736(66)92986-2
- Deibert DC, DeFronzo RA. Epinephrine-induced insulin resistance in man. *J Clin Invest* (1980) 65:717–21. doi: 10.1172/JCI109718
- Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Pheochromocytoma. *Lancet* (2005) 366:665–75. doi: 10.1016/S0140-6736(05)67139-5
- Stenstrom G, Sjoström L, Smith U. Diabetes mellitus in pheochromocytoma. Fasting blood glucose levels before and after surgery in 60 patients with pheochromocytoma. *Acta Endocrinol (Copenh)* (1984) 106:511–5. doi: 10.1530/acta.0.1060511
- Elenkova A, Matrozova J, Vasilev V, Robeva R, Zacharieva S. Prevalence and progression of carbohydrate disorders in patients with pheochromocytoma/

- paraganglioma: retrospective single-center study. *Ann Endocrinol (Paris)* (2020) 81:3–10. doi: 10.1016/j.ando.2020.01.001
12. Beninato T, Kluijfhout WP, Drake FT, Lim J, Kwon JS, Xiong M, et al. Resection of Pheochromocytoma Improves Diabetes Mellitus in the Majority of Patients. *Ann Surg Oncol* (2017) 24:1208–13. doi: 10.1245/s10434-016-5701-6
 13. Bole D, Simon B. Pheochromocytoma-induced hyperglycemia leading to misdiagnosis of type 1 diabetes mellitus. *AACE Clin Case Rep* (2017) 3:e83–6. doi: 10.4158/EP161210.CR
 14. Leng OM, Madathil AC. Remission of longstanding insulin-treated diabetes mellitus following surgical resection of pheochromocytoma. *AACE Clin Case Rep* (2019) 5:e62–5. doi: 10.4158/ACCR-2018-0091
 15. Isotani H, Fujimura Y, Furukawa K, Morita K. Diabetic ketoacidosis associated with the pheochromocytoma of youth. *Diabetes Res Clin Pract* (1996) 34:57–60. doi: 10.1016/s0168-8227(96)01330-7
 16. Ishii C, Inoue K, Negishi K, Tane N, Awata T, Katayama S. Diabetic ketoacidosis in a case of pheochromocytoma. *Diabetes Res Clin Pract* (2001) 54:137–42. doi: 10.1016/s0168-8227(01)00261-3
 17. Lee IS, Lee TW, Chang CJ, Chien YM, Lee TI. Pheochromocytoma presenting as hyperglycemic hyperosmolar syndrome and unusual fever. *Intern Emerg Med* (2015) 10:753–5. doi: 10.1007/s11739-015-1217-5
 18. Akiba M, Kodama T, Ito Y, Obara T, Fujimoto Y. Hypoglycemia induced by excessive rebound secretion of insulin after removal of pheochromocytoma. *World J Surg* (1990) 14:317–24. doi: 10.1007/BF01658514
 19. Araki S, Kijima T, Waseda Y, Komai Y, Nakanishi Y, Uehara S, et al. Incidence and predictive factors of hypoglycemia after pheochromocytoma resection. *Int J Urol* (2019) 26:273–7. doi: 10.1111/iju.13864
 20. Strosberg AD. Structure, function, and regulation of adrenergic receptors. *Protein Sci* (1993) 2:1198–209. doi: 10.1002/pro.5560020802
 21. Fagerholm V, Grønroos T, Marjamki P, Viljanen T, Scheinin M, Haaparanta M. Altered glucose homeostasis in alpha2A-adrenoceptor knockout mice. *Eur J Pharmacol* (2004) 505:243–52. doi: 10.1016/j.ejphar.2004.10.023
 22. Hu X, Friedman D, Hill S, Caprioli R, Nicholson W, Powers AC, et al. Proteomic exploration of pancreatic islets in mice null for the alpha2A adrenergic receptor. *J Mol Endocrinol* (2005) 35:73–88. doi: 10.1677/jme.1.01764
 23. Vieira E, Liu YJ, Gylfe E. Involvement of alpha1 and beta-adrenoceptors in adrenaline stimulation of the glucagon-secreting mouse alpha-cell. *Naunyn-Schmiedeberg Arch Pharmacol* (2004) 369:179–83. doi: 10.1007/s00210-003-0858-5
 24. Hamilton A, Zhang Q, Salehi A, Willems M, Knudsen JG, Ringgaard AK, et al. Adrenaline stimulates glucagon secretion by Tpc2-dependent Ca(2+) mobilization from acidic stores in pancreatic α -cells. *Diabetes* (2018) 67(6):1128–39. doi: 10.2337/db17-1102
 25. Philipson LH. Beta-agonists and metabolism. *J Allergy Clin Immunol* (2002) 110:S313–7. doi: 10.1067/mai.2002.129702
 26. de Souza CJ, Burkey BF. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. *Curr Pharm Des* (2001) 7:1433–49. doi: 10.2174/1381612013397339
 27. Boschmann M, Krupp G, Luft FC, Klaus S, Jordan J. In vivo response to alpha (1)-adrenoreceptor stimulation in human white adipose tissue. *Obes Res* (2002) 10:555–8. doi: 10.1038/oby.2002.75
 28. Shi T, Papay RS, Perez DM. The role of α (1)-adrenergic receptors in regulating metabolism: increased glucose tolerance, leptin secretion and lipid oxidation. *J Recept Signal Transduct Res* (2017) 37:124–32. doi: 10.1080/10799893.2016.1193522
 29. Shiuchi T, Toda C, Okamoto S, Coutinho EA, Saito K, Miura S, et al. Induction of glucose uptake in skeletal muscle by central leptin is mediated by muscle β 2-adrenergic receptor but not by AMPK. *Sci Rep* (2017) 7:15141. doi: 10.1038/s41598-017-15548-6
 30. Mukaida S, Sato M, Öberg AI, Dehvari N, Olsen JM, Kocan M, et al. BRL37344 stimulates GLUT4 translocation and glucose uptake in skeletal muscle via β (2)-adrenoceptors without causing classical receptor desensitization. *Am J Physiol Regul Integr Comp Physiol* (2019) 316:R666–77. doi: 10.1152/ajpregu.00285.2018
 31. Ritter JM, Flower R, Henderson G, Loke YK, MacEwan D, Rang HP. *Rang & Dale's Pharmacology*. 9th ed. United Kingdom: Elsevier (2020).
 32. Komada H, Hirota Y, So A, Nakamura T, Okuno Y, Fukuoka H, et al. Insulin Secretion and Insulin Sensitivity Before and After Surgical Treatment of Pheochromocytoma or Paraganglioma. *J Clin Endocrinol Metab* (2017) 102:3400–5. doi: 10.1210/jc.2017-00357
 33. Petrák O, Klimová J, Mráz M, Haluzíková D, Doležalová RP, Kratochvílová H, et al. Pheochromocytoma with adrenergic biochemical phenotype shows decreased GLP-1 secretion and impaired glucose tolerance. *J Clin Endocrinol Metab* (2020) 105:dgaal54. doi: 10.1210/clinem/dgaa154
 34. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. *Nat Rev Endocrinol* (2012) 8:728–42. doi: 10.1038/nrendo.2012.140
 35. Blüher M, Windgassen M, Paschke R. Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma. *Diabetes Care* (2000) 23:1591–2. doi: 10.2337/diacare.23.10.1591
 36. Wiesner TD, Blüher M, Windgassen M, Paschke R. Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma. *J Clin Endocrinol Metab* (2003) 88:3632–6. doi: 10.1210/jc.2003-030000
 37. Diamanti-Kandarakis E, Zapanti E, Peridis MH, Ntavos P, and Mastorakos G. Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment. *Hormones (Athens)* (2003) 2:61–6. doi: 10.14310/horm.2002.1184
 38. Guclu F, Taskiran E, Kaypak MA, Akmese A. Insulin resistance on pheochromocytoma. *Endocr Pract* (2017) 23:10A.
 39. DiSalvo RJ, Bloom WL, Brust AA, Ferguson RW, Ferris EB. A comparison of the metabolic and circulatory effects of epinephrine, nor-epinephrine and insulin hypoglycemia with observations on the influence of autonomic blocking agents. *J Clin Invest* (1956) 35:568–77. doi: 10.1172/JCI103310
 40. Abe I, Fujii H, Ohishi H, Sugimoto K, Minezaki M, Nakagawa M, et al. Differences in the actions of adrenaline and noradrenaline with regard to glucose intolerance in patients with pheochromocytoma. *Endocr J* (2019) 66:187–92. doi: 10.1507/endocrj.EJ18-0407
 41. Harada K, Kitaguchi T, Tsuboi T. Integrative function of adrenaline receptors for glucagon-like peptide-1 exocytosis in enteroendocrine L cell line GLUTag. *Biochem Biophys Res Commun* (2015) 460:1053–8. doi: 10.1016/j.bbrc.2015.03.151
 42. Hansen L, Lampert S, Mineo H, Holst JJ. Neural regulation of glucagon-like peptide-1 secretion in pigs. *Am J Physiol Endocrinol Metab* (2004) 287:E939–47. doi: 10.1152/ajpendo.00197.2004
 43. di Paolo S, de Pergola G, Cospite MR, Guastamacchia E, Cignarelli M, Balice A, et al. Beta-adrenoceptors desensitization may modulate catecholamine induced insulin resistance in human pheochromocytoma. *Diabetes Metab* (1989) 15:409–15.
 44. van Berkel A, Lenders JW, Timmers HJ. Diagnosis of endocrine disease: Biochemical diagnosis of pheochromocytoma and paraganglioma. *Eur J Endocrinol* (2014) 170:R109–19. doi: 10.1530/EJE-13-0882

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Abe, Islam and Lam. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.